TENAX THERAPEUTICS, INC.
Close on Oct 19, 2026
- Market cap
- $77.32M
- P/E (TTM)
- –
- Dividend yield
- –
About Tenax Therapeutics
Pharmaceutical Preparations, SIC 2834
Tenax Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for cardiopulmonary conditions. The company's lead clinical pipeline concentrates on oral levosimendan, being evaluated in late-stage Phase 3 clinical trials, including the LEVEL and LEVEL-2 studies, for pulmonary hypertension associated with heart failure with preserved ejection fraction. In addition, the firm maintains an interest in exploring imatinib for pulmonary hypertension applications. Its therapeutic candidates are designed to treat cardiovascular and pulmonary disorders in patients facing conditions with few or no approved treatment options.
The company operates primarily through research, clinical trial development, and regulatory engagement in the United States and internationally. It does not sell commercial drug products and relies on external collaborative arrangements, clinical research organizations, and specialized third parties to formulate products and conduct studies. Tenax Therapeutics maintains its principal executive offices in Chapel Hill, North Carolina.
Summary of the business section of Tenax Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- TENAX THERAPEUTICS, INC.
- Founded
- 1967
- Headquarters
- Chapel Hill, NC
- Address
- 101 Glen Lennox Drive, Suite 300 27517
- Phone
- (919) 855-2100
- Employees
- 14, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Cherry Bekaert LLP, Raleigh, North Carolina
Stock & identifiers
- Ticker
- TENX
- Exchange
- Nasdaq
- Shares outstanding
- 37M, Jul 28, 2026
- Public float
- $23.84M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-80 reverse, Jan 3, 2024; 1-for-20 reverse, Jan 5, 2023; 1-for-20 reverse, Apr 2, 2018; 1-for-20 reverse, Feb 26, 2018; 1-for-20 reverse, Jun 26, 2013; 1-for-20 reverse, May 13, 2013; 1-for-15 reverse, Nov 9, 2009
- SEC CIK
- 34956
- CUSIP
- 88032L605
- ISIN
- US88032L6056
- LEI
- 549300J03O6B1IJ2B606
- EIN
- 26-2593535
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Christopher Thomas Giordano | CEO, Director | 22,174 |
| Stuart Rich | Chief Medical Officer, Director | 12,654 |
| Thomas R. Staab Ii | Chief Financial Officer | 15,675 |
| Thomas McGauley | Interim CFO | 8,000 |
| Declan Doogan | Director | 55,274 |
| Michael H. Davidson | Director | 2,881 |
| Gerald T. Proehl | Director | 1,667 |
| June Sherie Almenoff | Director | 3,986 |
| Robyn Hunter | Director | 0 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Christopher T. Giordano | $8.08M | $21.67M | $1.87M | $1 | – |
| FY2024 Christopher T. Giordano | $7.40M | $7.70M | $1.72M | $0 | – |
| FY2023 Christopher T. Giordano | $644.77K | $515.68K | $323.76K | $1 | – |
| FY2022 Christopher T. Giordano | $667.33K | $652.05K | $344.92K | $11 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 14 full-time employees and two part-time employees.”
Corporate history
Events identified from SEC filings